IP Group plc
IP Group plc
Our global sites
IP Group case study on Pfizer drug royalty interest

HealthTech

Featured

From UK science to global scale: IP Group’s role in Pfizer’s obesity drug programme

The value crystallising across IP Group’s portfolio is often the result of decades of foundational science.

Read case study

IP Group case study on Artios
  • HealthTech
  • Impact stories

Artios: Defining DNA Damage Response (DDR)-based therapeutics in cancer
IP Group case study on Hysata
  • CleanTech
  • Impact stories

Hysata: Redefining the economics of green hydrogen
IP Group case study on Intrinsic
  • DeepTech
  • Impact stories

Intrinsic: Specialising in next-generation non-volatile random-access memory (ReRAM) technology
IP Group insight on its role in Pfizer’s obesity drug programme
  • HealthTech

From UK science to global scale: IP Group’s role in Pfizer’s obesity drug programme
IP Group insight on Intelligent Ultrasound
  • HealthTech

Intelligent Ultrasound: AI for Safer, Smarter Scanning
  • HealthTech

Spotlighting: Genomics

Dr Lee Thornton discussing IP Group portfolio company Intrinsic
  • DeepTech

Spotlighting: Intrinsic

Mike Molinari of IP Group Australia talking about portfolio company Hysata
  • CleanTech

Spotlighting: Hysata

IP Group insight on Mixergy
  • CleanTech

Mixergy: The forefront of smart hot water solutions and grid optimisation

IP Group insight on sale of Garrison to Everfox
  • DeepTech

Substantial return from hardsec pioneer Garrison
Image of woman with phone for IP Group Case Study on Featurespace exit
  • DeepTech

Featurespace: Our Largest Exit to Date
  • DeepTech

How WaveOptics became one of the biggest ever exits for a venture-backed “deeptech” start-up in Europe
Load more15

Showing XX of 15

Load more

Related pages

Investor

Investor relations

Our impact

Our impact